Evidence Level
Strong
2 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

Potassium citrate is potassium combined with citric acid — distinct from potassium chloride (most common supplemental form) by its alkalinizing effect and FDA-approved use for KIDNEY STONE PREVENTION (Urocit-K® prescription). Lower risk of GI ulceration than potassium chloride. Used both as nutritional potassium and as urinary alkalinizer for calcium oxalate, uric acid, and cystine stone prevention.

Studied Dose Nutritional: 100-500 mg/day; Pharmaceutical for stones: 30-90 mEq/day (Urocit-K®, prescription)
Active Compound Potassium citrate (tripotassium citrate)

Benefits

Kidney Stone Prevention (FDA-Approved)

Potassium citrate is FDA-APPROVED (Urocit-K® prescription) for prevention of calcium oxalate, uric acid, and cystine kidney stones. Mechanism: raises urinary citrate (which inhibits calcium oxalate crystallization) and urinary pH (which prevents uric acid stones). Standard urology care for recurrent stone-formers.

Urinary Alkalinizer

Citrate metabolizes to bicarbonate — raises urinary pH. Used for: gout (uric acid stones), cystinuria (cystine stones), and adjunct in some chemotherapy protocols (urinary alkalinization to reduce kidney damage).

Bone Health (Modest Evidence)

Potassium citrate may modestly support bone health by buffering metabolic acid load (typical Western diets are net-acid-producing). Some evidence for reduced bone resorption markers; effect modest. Whole-diet approach (DASH, Mediterranean) more impactful than single supplement.

Blood Pressure Modest Reduction

Adequate potassium intake reduces blood pressure; potassium citrate provides supplemental potassium without GI ulceration risk of potassium chloride. Modest BP reduction comparable to other potassium sources.

Lower GI Toxicity than Potassium Chloride

Potassium chloride tablets can cause GI ulceration if not adequately diluted. Potassium citrate has less GI toxicity — preferred for patients sensitive to chloride forms or with prior GI issues.

Mechanism of action

1

Citrate to Bicarbonate Conversion

Absorbed citrate is metabolized in liver to bicarbonate — neutralizes metabolic acid load and raises urinary pH. Urinary citrate excretion increases, providing the stone-prevention mechanism.

2

Calcium Oxalate Stone Inhibition

Urinary citrate binds calcium and reduces calcium oxalate supersaturation — major mechanism for calcium oxalate stone prevention. Hypocitraturia is a major risk factor for these stones.

3

Urinary pH Elevation

Raised urinary pH prevents uric acid stone formation (uric acid is more soluble at higher pH) and cystine stone formation. Targeted pH 6.5-7.0 for stone prevention.

4

Acid-Base Buffering

Bicarbonate generation buffers chronic mild metabolic acidosis from typical Western diets — proposed mechanism for bone-sparing effects.

Clinical trials

1
Potassium Citrate for Calcium Oxalate Stone Prevention — Trials

Multiple clinical trials of potassium citrate (30-60 mEq/day) for prevention of recurrent calcium oxalate kidney stones.

Recurrent calcium oxalate stone-formers.

Potassium citrate significantly reduces recurrent stone formation vs placebo. Standard urology care; recommended in AUA stone prevention guidelines.

2
Potassium Citrate for Bone Health

Pooled analysis of potassium citrate effects on bone turnover markers and bone density.

Pooled across bone health clinical trials.

Potassium citrate modestly reduces bone resorption markers and may slow bone loss. Effect sizes modest. Bone density changes inconsistent across trials. Adjunctive role only.

Side effects and drug interactions

Common Potential side effects

GI upset (nausea, diarrhea) — generally mild.
HYPERKALEMIA risk in CKD or with potassium-sparing medications — POTENTIALLY FATAL.
Pill burden — therapeutic stone-prevention doses require multiple large pills.
Metallic/salty taste with liquid forms.
Less GI ulceration than potassium chloride (relative advantage).

Important Drug interactions

ACE inhibitors / ARBs — increase potassium retention; HYPERKALEMIA RISK; monitor potassium.
Aldosterone antagonists (spironolactone, eplerenone) — HYPERKALEMIA RISK; very serious; monitor closely.
Potassium-sparing diuretics (amiloride, triamterene) — HYPERKALEMIA RISK.
NSAIDs — reduce potassium excretion modestly.
TRIMETHOPRIM — reduces potassium excretion; potential hyperkalemia.
Heparin — reduces potassium excretion.
Tetracyclines/quinolones — chelation; separate by 2 hours.
Aluminum-containing drugs — citrate enhances aluminum absorption; CAUTION in CKD/dialysis.

Frequently asked questions about Potassium Citrate

What is potassium citrate used for?

Potassium citrate provides potassium in an alkalizing form, and is notably used to help prevent certain kidney stones by making urine less acidic and raising urinary citrate. It also supports bone and a healthy acid-base balance.

Does potassium citrate help with kidney stones?

Yes, it is a recognized tool (often by prescription) for reducing the formation of calcium and uric acid kidney stones, because it raises urine citrate and pH, which discourages stone crystals. Use it for this purpose under a doctor's guidance.

How much potassium citrate should I take?

Over-the-counter potassium is limited to 99 mg per serving; the higher doses used for kidney stones or bone are prescription-strength and medically supervised. For general use, most potassium should come from fruits and vegetables.

Is potassium citrate safe?

At small supplemental amounts it is generally well tolerated and gentler than potassium chloride. People with kidney disease or on potassium-raising medications should avoid it without medical supervision, due to the risk of high potassium.

What is Potassium Citrate?

Potassium citrate is potassium combined with citric acid — distinct from potassium chloride (most common supplemental form) by its alkalinizing effect and FDA-approved use for KIDNEY STONE PREVENTION (Urocit-K® prescription). Lower risk of GI ulceration than potassium chloride.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. The Journal of Urology. 1993;150(6):1761-1764. doi: 10.1016/s0022-5347(17)35888-3.PubMedUsed to support: Landmark RCT establishing the best-supported use: potassium citrate raised urinary citrate and markedly reduced calcium stone recurrence vs placebo. Honest framing: benefit is clearest in hypocitraturic stone-formers; GI upset can limit adherence.
  2. Pak CY, Sakhaee K, Fuller C Successful management of uric acid nephrolithiasis with potassium citrate. Kidney International. 1986;30(3):422-428. doi: 10.1038/ki.1986.201.PubMedUsed to support: Supports the uric-acid-stone use: potassium citrate alkalinizes urine, dissolving and preventing uric-acid stones. Honest framing: requires monitoring to avoid over-alkalinization, and it is contraindicated in hyperkalemia/renal failure.
  3. Jehle S, Zanetti A, Muser J, Hulter HN, Krapf R Partial neutralization of the acidogenic Western diet with potassium citrate increases bone mass in postmenopausal women with osteopenia. Journal of the American Society of Nephrology. 2006;17(11):3213-3222. doi: 10.1681/ASN.2006030233.PubMedUsed to support: Supports the bone hypothesis: neutralizing dietary acid load with potassium citrate increased bone mass in osteopenic women. Honest framing: this positive bone signal is smaller and less consistent than the clear stone-prevention effect.
  4. Jehle S, Hulter HN, Krapf R Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2013;98(1):207-217. doi: 10.1210/jc.2012-3099.PubMedUsed to support: A larger RCT showing potassium citrate improved bone density and microarchitecture in older adults. Honest framing: bone and blood-pressure benefits remain modest and mixed across trials, so stone prevention is still the strongest evidence-based use.